HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

BCL2-specific inhibitor ABT-199 synergizes strongly with cytarabine against the early immature LOUCY cell line but not more-differentiated T-ALL cell lines.

AuthorsN M Anderson, I Harrold, M R Mansour, T Sanda, M McKeown, N Nagykary, J E Bradner, G Lan Zhang, A T Look, H Feng
JournalLeukemia (Leukemia) Vol. 28 Issue 5 Pg. 1145-8 (May 2014) ISSN: 1476-5551 [Electronic] England
PMID24342948 (Publication Type: Letter, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • Bridged Bicyclo Compounds, Heterocyclic
  • Proto-Oncogene Proteins c-bcl-2
  • Sulfonamides
  • Cytarabine
  • venetoclax
Topics
  • Antineoplastic Agents (pharmacology)
  • Bridged Bicyclo Compounds, Heterocyclic (pharmacology)
  • Cell Differentiation
  • Cell Line, Tumor
  • Cytarabine (pharmacology)
  • Drug Synergism
  • Humans
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (drug therapy, pathology)
  • Proto-Oncogene Proteins c-bcl-2 (antagonists & inhibitors)
  • Sulfonamides (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: